Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ethnicity in systemic AL amyloidosis may impact risk stratification.
Khwaja J, Ravichandran S, Cohen O, Foard D, Martinez-Naharro A, Venneri L, Whelan C, Hawkins PN, Gillmore J, Lachmann HJ, Mahmood S, Fontana M, Wechalekar A. Khwaja J, et al. Among authors: venneri l. Haematologica. 2025 Jan 16. doi: 10.3324/haematol.2024.286746. Online ahead of print. Haematologica. 2025. PMID: 39815808 Free article.
Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy.
Ioannou A, Razvi Y, Porcari A, Rauf MU, Martinez-Naharro A, Venneri L, Kazi S, Pasyar A, Luxhøj CM, Petrie A, Moody W, Steeds RP, Sperry BW, Witteles RM, Whelan C, Wechalekar A, Lachmann H, Hawkins PN, Solomon SD, Gillmore JD, Fontana M. Ioannou A, et al. Among authors: venneri l. JAMA Cardiol. 2025 Jan 1;10(1):50-58. doi: 10.1001/jamacardio.2024.4578. JAMA Cardiol. 2025. PMID: 39550765 Free PMC article.
Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy.
Razvi Y, Judge DP, Martinez-Naharro A, Ioannou A, Venneri L, Patel R, Gillmore JD, Kellman P, Edwards L, Taubel J, Du J, Tamby JF, Castaño A, Siddhanti S, Katz L, Fox JC, Fontana M. Razvi Y, et al. Among authors: venneri l. Circ Heart Fail. 2024 Dec;17(12):e012135. doi: 10.1161/CIRCHEARTFAILURE.124.012135. Epub 2024 Oct 28. Circ Heart Fail. 2024. PMID: 39465243 Free PMC article. No abstract available.
Microvascular obstruction in cardiac amyloidosis.
Netti L, Ioannou A, Martinez-Naharro A, Razvi Y, Porcari A, Venneri L, Maestrini V, Knight D, Virsinskaite R, Rauf MU, Kotecha T, Patel RK, Wechelakar A, Lachmann H, Kellman P, Manisty C, Moon J, Hawkins PN, Gillmore JD, Fontana M. Netti L, et al. Among authors: venneri l. Eur J Heart Fail. 2024 Oct 18. doi: 10.1002/ejhf.3481. Online ahead of print. Eur J Heart Fail. 2024. PMID: 39422337
Refining prognostication in systemic AL amyloidosis: limited value of dFLC.
Khwaja J, Ravichandran S, Bomsztyk J, Cohen O, Foard D, Martinez-Naharro A, Venneri L, Fontana M, Whelan C, Hawkins PN, Gillmore JD, Lachmann HJ, Mahmood S, Wechalekar A. Khwaja J, et al. Among authors: venneri l. Amyloid. 2024 Dec;31(4):353-355. doi: 10.1080/13506129.2024.2406845. Epub 2024 Sep 23. Amyloid. 2024. PMID: 39311543 No abstract available.
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.
Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, Damy T, Garcia-Pavia P, Taubel J, Solomon SD, Sheikh FH, Tahara N, González-Costello J, Tsujita K, Morbach C, Pozsonyi Z, Petrie MC, Delgado D, Van der Meer P, Jabbour A, Bondue A, Kim D, Azevedo O, Hvitfeldt Poulsen S, Yilmaz A, Jankowska EA, Algalarrondo V, Slugg A, Garg PP, Boyle KL, Yureneva E, Silliman N, Yang L, Chen J, Eraly SA, Vest J, Maurer MS; HELIOS-B Trial Investigators and Collaborators. Fontana M, et al. N Engl J Med. 2025 Jan 2;392(1):33-44. doi: 10.1056/NEJMoa2409134. Epub 2024 Aug 30. N Engl J Med. 2025. PMID: 39213194 Clinical Trial.
Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis.
Porcari A, Masi A, Martinez-Naharro A, Razvi Y, Patel R, Ioannou A, Rauf MU, Sinigiani G, Wisniowski B, Filisetti S, Currie-Cathey J, O'Beara S, Kotecha T, Knight D, Moon JC, Sinagra G, Virsinskaite R, Gilbertson J, Venneri L, Petrie A, Lachmann H, Whelan C, Kellman P, Ravichandran S, Cohen O, Mahmood S, Manisty C, Hawkins PN, Gillmore JD, Wechalekar AD, Fontana M. Porcari A, et al. Among authors: venneri l. JAMA Cardiol. 2024 Nov 1;9(11):982-989. doi: 10.1001/jamacardio.2024.2555. JAMA Cardiol. 2024. PMID: 39167388 Free PMC article.
Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis.
Nitsche C, Ioannou A, Patel RK, Razvi Y, Porcari A, Rauf MU, Bandera F, Aimo A, Emdin M, Martinez-Naharro A, Venneri L, Petrie A, Wechalekar A, Lachmann H, Hawkins PN, Gillmore JD, Fontana M. Nitsche C, et al. Among authors: venneri l. Eur J Heart Fail. 2024 Sep;26(9):2008-2012. doi: 10.1002/ejhf.3354. Epub 2024 Jun 23. Eur J Heart Fail. 2024. PMID: 38922779
Response rates to second-line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib-based regime.
Bomsztyk J, Ravichandran S, Khwaja J, Cohen O, Rauf MU, Foard D, Martinez-Naharro A, Venneri L, Whelan C, Fontana M, Hawkins PN, Gillmore J, Lachmann H, Mahmood S, Wechalekar AD. Bomsztyk J, et al. Among authors: venneri l. Br J Haematol. 2024 Jul;205(1):138-145. doi: 10.1111/bjh.19529. Epub 2024 Jun 5. Br J Haematol. 2024. PMID: 38840512
Native myocardial T1 and right ventricular size by CMR predict outcome in systemic sclerosis-associated pulmonary hypertension.
Knight DS, Virsinskaite R, Karia N, Cole AR, Maclean RH, Brown JT, Patel RK, Razvi Y, Venneri L, Kotecha T, Martinez-Naharro A, Kellman P, Scott-Russell AM, Schreiber BE, Ong VH, Denton CP, Fontana M, Coghlan JG, Muthurangu V. Knight DS, et al. Among authors: venneri l. Rheumatology (Oxford). 2024 Oct 1;63(10):2678-2683. doi: 10.1093/rheumatology/keae141. Rheumatology (Oxford). 2024. PMID: 38759116 Free PMC article.
64 results